Passage Bio (PASG) Competitors $0.52 -0.03 (-4.58%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.52 +0.00 (+0.04%) As of 02/21/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PASG vs. CHRS, BMEA, BDTX, CABA, TSVT, KYTX, SGMT, IVA, RENB, and TELOShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Coherus BioSciences (CHRS), Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Cabaletta Bio (CABA), 2seventy bio (TSVT), Kyverna Therapeutics (KYTX), Sagimet Biosciences (SGMT), Inventiva (IVA), Renovaro (RENB), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Coherus BioSciences Biomea Fusion Black Diamond Therapeutics Cabaletta Bio 2seventy bio Kyverna Therapeutics Sagimet Biosciences Inventiva Renovaro Telomir Pharmaceuticals Coherus BioSciences (NASDAQ:CHRS) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Which has more volatility & risk, CHRS or PASG? Coherus BioSciences has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Does the media prefer CHRS or PASG? In the previous week, Passage Bio had 2 more articles in the media than Coherus BioSciences. MarketBeat recorded 2 mentions for Passage Bio and 0 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score. Company Overall Sentiment Coherus BioSciences Neutral Passage Bio Neutral Is CHRS or PASG more profitable? Passage Bio has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Passage Bio's return on equity.Company Net Margins Return on Equity Return on Assets Coherus BioSciences-0.15% N/A -24.44% Passage Bio N/A -72.53%-52.10% Which has preferable valuation and earnings, CHRS or PASG? Passage Bio has lower revenue, but higher earnings than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus BioSciences$257.24M0.48-$237.89M-$0.08-13.38Passage BioN/AN/A-$102.06M-$1.17-0.45 Do analysts rate CHRS or PASG? Coherus BioSciences currently has a consensus price target of $5.38, suggesting a potential upside of 402.34%. Passage Bio has a consensus price target of $7.75, suggesting a potential upside of 1,376.75%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Coherus BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer CHRS or PASG? Coherus BioSciences received 396 more outperform votes than Passage Bio when rated by MarketBeat users. However, 68.42% of users gave Passage Bio an outperform vote while only 65.31% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformCoherus BioSciencesOutperform Votes44865.31% Underperform Votes23834.69% Passage BioOutperform Votes5268.42% Underperform Votes2431.58% Do institutionals and insiders hold more shares of CHRS or PASG? 72.8% of Coherus BioSciences shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 7.6% of Coherus BioSciences shares are held by company insiders. Comparatively, 4.3% of Passage Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryPassage Bio beats Coherus BioSciences on 9 of the 16 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.97M$3.11B$5.84B$9.15BDividend YieldN/A1.55%4.75%3.85%P/E Ratio-0.4527.4925.4719.00Price / SalesN/A329.47447.5876.30Price / CashN/A168.8738.0134.83Price / Book0.263.687.644.62Net Income-$102.06M-$71.72M$3.18B$245.85M7 Day Performance-6.29%-2.50%-1.99%-2.68%1 Month Performance-11.93%-0.32%-0.42%-2.19%1 Year Performance-57.68%-12.32%16.51%12.84% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio2.5467 of 5 stars$0.52-4.6%$7.75+1,376.8%-57.7%$33.97MN/A-0.45130News CoverageCHRSCoherus BioSciences3.6663 of 5 stars$1.18+1.7%$5.38+355.5%-56.9%$136.75M$257.24M-14.75330BMEABiomea Fusion3.3309 of 5 stars$3.73+3.3%$39.36+955.3%-77.4%$135.17MN/A-0.9350Positive NewsBDTXBlack Diamond Therapeutics3.3793 of 5 stars$2.37+1.3%$15.50+554.0%-53.7%$134.10MN/A-1.7890Short Interest ↓Positive NewsCABACabaletta Bio2.2549 of 5 stars$2.71+0.4%$22.71+738.2%-90.7%$132.47MN/A-1.2650Analyst ForecastTSVT2seventy bio2.1861 of 5 stars$2.54-0.4%$7.20+183.5%-53.2%$131.03M$45.62M-1.37440Analyst ForecastNews CoveragePositive NewsKYTXKyverna Therapeutics1.1513 of 5 stars$3.03-0.3%$25.71+748.7%-89.9%$130.81M$7.03M0.0096SGMTSagimet Biosciences1.7999 of 5 stars$4.25-3.4%$23.00+441.2%-38.9%$130.35M$2M0.008News CoverageIVAInventiva1.9923 of 5 stars$2.47-0.4%$13.25+436.4%-13.1%$129.63M$18.91M0.00100Analyst ForecastNews CoverageRENBRenovaro0.7629 of 5 stars$0.81+9.0%N/A-61.1%$128.39MN/A-0.8420Earnings ReportNews CoverageGap UpTELOTelomir Pharmaceuticals2.2879 of 5 stars$4.29+0.5%N/A-54.8%$127.67MN/A-7.401Analyst ForecastNews Coverage Related Companies and Tools Related Companies CHRS Alternatives BMEA Alternatives BDTX Alternatives CABA Alternatives TSVT Alternatives KYTX Alternatives SGMT Alternatives IVA Alternatives RENB Alternatives TELO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PASG) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PASG Stock Alerts